Prevalence of Carriers of Intermediate and Pathological Polyglutamine Disease–Associated Alleles Among Large Population-Based Cohorts

Orr, 2012, Polyglutamine neurodegeneration: expanded glutamines enhance native functions., Curr Opin Genet Dev, 22, 251, 10.1016/j.gde.2012.01.001

Durr, 2010, Autosomal dominant cerebellar ataxias: polyglutamine expansions and beyond., Lancet Neurol, 9, 885, 10.1016/S1474-4422(10)70183-6

Bates, 2015, Huntington disease., Nat Rev Dis Primers, 1, 15005, 10.1038/nrdp.2015.5

Penninx, 2008, The Netherlands Study of Depression and Anxiety (NESDA): rationale, objectives and methods., Int J Methods Psychiatr Res, 17, 121, 10.1002/mpr.v17:3

Comijs, 2011, The Netherlands Study of Depression in Older Persons (NESDO): a prospective cohort study., BMC Res Notes, 4, 524, 10.1186/1756-0500-4-524

de Mutsert, 2013, The Netherlands Epidemiology of Obesity (NEO) study: study design and data collection., Eur J Epidemiol, 28, 513, 10.1007/s10654-013-9801-3

Shepherd, 2002, Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial., Lancet, 360, 1623, 10.1016/S0140-6736(02)11600-X

der Wiel, 2002, A high response is not essential to prevent selection bias: results from the Leiden 85-plus Study., J Clin Epidemiol, 55, 1119, 10.1016/S0895-4356(02)00505-X

Gardiner, Repeat length variations in polyglutamine disease–associated genes affect body mass index, Int J Obes

Benjamini, 1995, Controlling the false discovery rate: a practical and powerful approach to multiple testing., J R Stat Soc B, 57, 289, 10.1111/j.2517-6161.1995.tb02031.x

Wheeler, 2007, Factors associated with HD CAG repeat instability in Huntington disease., J Med Genet, 44, 695, 10.1136/jmg.2007.050930

Cubo, 2016, Clinical manifestations of intermediate allele carriers in Huntington disease., Neurology, 87, 571, 10.1212/WNL.0000000000002944

Killoran, 2013, Characterization of the Huntington intermediate CAG repeat expansion phenotype in PHAROS., Neurology, 80, 2022, 10.1212/WNL.0b013e318294b304

Gardiner, 2017, Large normal-range TBP and ATXN7 CAG repeat lengths are associated with increased lifetime risk of depression., Transl Psychiatry, 7, e1143, 10.1038/tp.2017.116

Gardiner, 2017, Huntingtin gene repeat size variations affect risk of lifetime depression., Transl Psychiatry, 7, 1277, 10.1038/s41398-017-0042-1

Kay, 2016, Huntington disease reduced penetrance alleles occur at high frequency in the general population., Neurology, 87, 282, 10.1212/WNL.0000000000002858

Langbehn, 2004, A new model for prediction of the age of onset and penetrance for Huntington’s disease based on CAG length., Clin Genet, 65, 267, 10.1111/j.1399-0004.2004.00241.x

Menon, 2013, The role of interruptions in polyQ in the pathology of SCA1., PLoS Genet, 9, e1003648, 10.1371/journal.pgen.1003648

Semaka, 2013, CAG size–specific risk estimates for intermediate allele repeat instability in Huntington disease., J Med Genet, 50, 696, 10.1136/jmedgenet-2013-101796

Takano, 1998, Close associations between prevalences of dominantly inherited spinocerebellar ataxias with CAG-repeat expansions and frequencies of large normal CAG alleles in Japanese and Caucasian populations., Am J Hum Genet, 63, 1060, 10.1086/302067

Kay, 2018, The molecular epidemiology of Huntington disease is related to intermediate allele frequency and haplotype in the general population., Am J Med Genet B Neuropsychiatr Genet, 177, 346, 10.1002/ajmg.b.32618

Tang, 2017, Profiling of short-tandem-repeat disease alleles in 12,632 human whole genomes., Am J Hum Genet, 101, 700, 10.1016/j.ajhg.2017.09.013

Opal, 1993, GeneReviews

Pulst, 1998, GeneReviews

Gomez, 1993, GeneReviews

Garden, 1993, GeneReviews

Toyoshima, 1993, GeneReviews

Caron, 1998, GeneReviews

Veneziano, 1993, GeneReviews

La Spada, 1993, GeneReviews

Paulson, 1998, GeneReviews